The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study
TerminatedPhase 1NCT05229653
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a randomized, single blinded, placebo-controlled trial to study the effectiveness of a subanesthetic dose (0.6 mg/kg) of ketamine versus placebo (saline) on postoperative pain and pain on adult female chronic pelvic pain patients undergoing robotic removal of endometriosis. The objective of the study is to explore the effect of a sub anesthetic dose of ketamine (0.6 mg/kg) vs. saline control on postoperative pain and recovery in chronic pelvic pain patients who have undergone robotic removal of endometriosis.
Study details
- Official title
- Phase I Randomized, Single-blind, Placebo-controlled, Single-center Study of the Effect of Postoperative Administration of Single Dose Ketamine on Pain and Recovery After Robotic Removal of Endometriosis in Patients With Chronic Pelvic Pain
- Conditions
- Interventions
- Sponsor
- NYU Langone Health
- Start date
- 2022-04-12
- Primary completion
- 2022-10-21
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Adults, aged 18 to 65 years old 2. Experiencing chronic pain, defined as experiencing moderate to severe pelvic pain for greater than 6 months 3. Scheduled to undergo robotic endometriosis removal surgery 4. Willing to comply with all study procedures and be available for the duration of the study. 5. Subject is medically stable. Exclusion Criteria: 1. Cognitive impairment (by history) or clinical signs of altered mental status such as confusion, amnesia, disorientation, fluctuating levels of alertness, etc. that may interference with adherence to study procedures and/or participant safety. 2. Past ketamine or phencyclidine misuse or abuse 3. Schizophrenia or history of psychosis 4. Known sensitivity or allergy to ketamine 5. Liver or renal insufficiency. 6. History of uncontrolled hypertension, chest pain, cardiac arrythmia, stroke, head trauma, intracranial mass or hemorrhage or pressure, glaucoma, acute globe injury, uncontrolled thyroid disease, porphyria, or any other contraindication to ketamine. Use of lamotrigine, alfentanil, physostigmine, and 4-aminopyridine are contraindicated 7. Pregnancy or nursing women 8. Currently participating in another pain interventional trial 9. Unwillingness to give informed consent 10. Non-English-speaking patients as the EHP-30 instrument has only been licensed to NYULH in English.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05229653